SHENZHEN, China, Sept. 2, 2024 /PRNewswire/ -- Growatt is proud to unveil the HELIOS 3600, the latest powerhouse in portable energy technology. Engineered for those who demand nothing less than maximum power and reliability, the HELIOS 3600 is a true power beast, ready to conquer any energy challenge you throw at it.
With a colossal battery capacity of 3686.4Wh and a continuous output of 3600W, it's capable of powering a wide range of devices and appliances. For those requiring even more power, connect two HELIOS 3600 units in parallel to achieve a maximum system capacity of 36kWh when paired with expansion batteries.
HELIOS 3600 offers flexible charging with 120V and 240V charging options, along with simultaneous XT60 and Anderson input charging. This ensures that your power station can be charged and ready in multiple ways, depending on your available resources. You may charge the HELIOS 3600 via wall outlets, solar panels, car chargers, RV pedestal chargers, or Anderson input – or combine methods for even faster charging speeds. It is equipped with 16 versatile outlets, including a NEMA TT-30 for RV enthusiasts and an Anderson output for solar or DIY projects, this beast is ready for any connection. You can tailor your power usage with myGro App to customize your power strategy by setting up the TOU Mode, Solar Focus Mode, or Emergency Backup Mode.
"The HELIOS 3600 is not just another power station; it's a comprehensive energy solution," said Lisa Zhang, Vice President of Marketing at Growatt. "With its unmatched power capacity, versatility, and smart features, it empowers users to take control of their energy needs in any situation, from everyday use to emergency scenarios."
The HELIOS 3600 will be available starting 2 September 2024 on GrowattPortable.com.
For more information, visit Growatt HELIOS 3600.
About Growatt:
Growatt is a pioneer in innovative energy solutions, dedicated to providing reliable and efficient power products that empower people to stay connected and safe in any situation. Our mission is to create reliable, sustainable, and user-friendly energy products that meet the evolving needs of our customers.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Meet the Power Beast: Growatt HELIOS 3600, The Ultimate Energy Solution for Every Challenge
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
